Participants with human complement serum bactericidal activity titres of 1:4 or greater, intention-to-treat population
| Strain (antigen assessed) | Group | At baseline | At 1 mo | At 3 mo | |||
|---|---|---|---|---|---|---|---|
| % (95% CI) | n/N | % (95% CI) | n/N | % (95% CI) | n/N | ||
| 44/76-SL (fHbp) | 4CMenB246-12* | 65 (38–86) | 11/17 | 100 (82–100) | 19/19 | NA | NA |
| rMenB246-12† | 45 (26–64) | 13/29 | 100 (88–100) | 28/28 | NA | NA | |
| 4CMenB-12‡ | 38 (9–76) | 3/8 | 100 (59–100) | 7/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 57 (29–82) | 8/14 | 100 (75–100) | 13/13 | 100 (75–100) | 13/13 | |
| Control¶ | 63 (46–77) | 25/40 | 89 (75–97) | 34/38 | 100 (90–100) | 36/36 | |
| 5/99 (NadA) | 4CMenB246-12* | 76 (50–93) | 13/17 | 100 (81–100) | 18/18 | NA | NA |
| rMenB246-12† | 43 (24–63) | 12/28 | 100 (88–100) | 28/28 | NA | NA | |
| 4CMenB-12‡ | 0 (0–37) | 0/8 | 100 (59–100) | 7/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 57 (29–82) | 8/14 | 100 (75–100) | 13/13 | 100 (75–100) | 13/13 | |
| Control¶ | 3 (0–13) | 1/40 | 76 (60–89) | 29/38 | 100 (90–100) | 36/36 | |
| NZ98/254 (PorA) | 4CMenB246-12* | 41 (18–67) | 7/17 | 89 (67–99) | 17/19 | NA | NA |
| rMenB246-12† | 3 (0–18) | 1/29 | 14 (4–33) | 4/28 | NA | NA | |
| 4CMenB-12‡ | 0 (0–37) | 0/8 | 100 (59–100) | 7/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 7 (0–34) | 1/14 | 15 (2–45) | 2/13 | 15 (2–45) | 2/13 | |
| Control¶ | 0 (0–9) | 1/40 | 66 (49–80) | 25/38 | 94 (81–99) | 34/36 | |
| M10713 (NHBA) | 4CMenB246-12* | 67 (38–88) | 10/15 | 94 (73–100) | 17/18 | NA | NA |
| rMenB246-12† | 68 (48–84) | 19/28 | 96 (82–100) | 27/28 | NA | NA | |
| 4CMenB-12‡ | 25 (3–65) | 2/8 | 86 (42–100) | 6/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 54 (25–81) | 7/13 | 100 (75–100) | 13/13 | 83 (52–98) | 10/12 | |
| Control¶ | 68 (51–81) | 27/40 | 76 (60–89) | 29/38 | 89 (74–97) | 32/36 | |
| M00-242922 | 4CMenB246-12* | 53 (28–77) | 9/17 | 100 (81–100) | 18/18 | NA | NA |
| rMenB246-12† | 18 (6–37) | 5/28 | 75 (55–89) | 21/28 | NA | NA | |
| 4CMenB-12‡ | 0 (0–37) | 0/8 | 100 (59–100) | 7/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 8 (0–36) | 1/13 | 54 (25–81) | 7/13 | 42 (15–72) | 5/12 | |
| Control¶ | 18 (8–34) | 7/39 | 49 (32–66) | 18/37 | 94 (81–99) | 33/35 | |
| M01-240101 | 4CMenB246-12* | 71 (44–90) | 12/17 | 100 (81–100) | 18/18 | NA | NA |
| rMenB246-12† | 71 (51–87) | 20/28 | 100 (88–100) | 28/28 | NA | NA | |
| 4CMenB-12‡ | 63 (24–91) | 5/8 | 100 (59–100) | 7/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 77 (46–95) | 10/13 | 100 (75–100) | 13/13 | 100 (74–100) | 12/12 | |
| Control¶ | 74 (58–87) | 29/39 | 97 (86–100) | 36/37 | 100 (90–100) | 35/35 | |
| M01-240355 | 4CMenB246-12* | 6 (0–29) | 1/17 | 50 (26–74) | 9/18 | NA | NA |
| rMenB246-12† | 25 (11–45) | 7/28 | 29 (13–49) | 8/28 | NA | NA | |
| 4CMenB-12‡ | 25 (3–65) | 2/8 | 71 (29–96) | 5/7 | 63 (24–91) | 5/8 | |
| rMenB-12§ | 15 (2–45) | 2/13 | 31 (9–61) | 4/13 | 8 (0–38) | 1/12 | |
| Control¶ | 18 (8–34) | 7/39 | 30 (16–47) | 11/37 | 69 (51–83) | 24/35 | |
| M01-240364 | 4CMenB246-12* | 88 (64–99) | 15/17 | 94 (73–100) | 17/18 | NA | NA |
| rMenB246-12† | 61 (41–78) | 17/28 | 82 (63–94) | 23/28 | NA | NA | |
| 4CMenB-12‡ | 50 (16–84) | 4/8 | 100 (59–100) | 7/7 | 100 (63–100) | 8/8 | |
| rMenB-12§ | 77 (46–95) | 10/13 | 100 (75–100) | 13/13 | 100 (74–100) | 12/12 | |
| Control¶ | 82 (66–92) | 31/38 | 86 (71–95) | 32/37 | 100 (90–100) | 34/34 | |
CI = confidence interval, fHbp = factor H binding protein, NA = not applicable, NadA = Neisseria adhesin A, NHBA = Neisseria heparin binding antigen, PorA = porin A.
↵* Participants who received 4 doses of 4CMenB vaccine at 2, 4, 6 and 12 months.
↵† Participants who received 4 doses of rMenB vaccine at 2, 4, 6 and 12 months.
↵‡ Participants who received 1 dose of 4CMenB at 12 months.
↵§ Participants who received 1 dose of rMenB vaccine at 12 months.
↵¶ Participants with no previous exposure to 4CMenB or rMenB vaccines.